Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study
Judith Trotman,
Peter Presgrave,
Duncan P. Carradice,
Douglas Stuart Lenton,
Maher K. Gandhi,
Tara Cochrane,
Xavier Badoux,
Julia Carlson,
Gloria Nkhoma,
Belinda Butcher,
Armin Nikpour,
Michael Fulham,
Anna M. Johnston
Affiliations
Judith Trotman
1 Haematology, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia
Peter Presgrave
3 Department of Haematology, Wollongong Hospital, NSW, Australia
Duncan P. Carradice
4 Department of Haematology and Medical Oncology, Western Health and University of Melbourne, St Albans, VIC, Australia
Douglas Stuart Lenton
5 Orange Hospital, NSW, Australia
Maher K. Gandhi
7 Princess Alexandra Hospital, Brisbane, QLD, Australia
Tara Cochrane
9 Department of Haematology, Gold Coast University Hospital, Southport, Australia
Xavier Badoux
11 University of New South Wales, Sydney, NSW, Australia
Julia Carlson
12 Australasian Leukaemia and Lymphoma Group, Richmond, VIC, Australia
Gloria Nkhoma
12 Australasian Leukaemia and Lymphoma Group, Richmond, VIC, Australia
Belinda Butcher
11 University of New South Wales, Sydney, NSW, Australia
Armin Nikpour
2 University of Sydney, Camperdown, NSW, Australia
Michael Fulham
2 University of Sydney, Camperdown, NSW, Australia
Anna M. Johnston
15 Department of Hematology, Royal Hobart Hospital, Hobart, TAS, Australia
